Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $9.33, for a total transaction of $159,701.61. Following the completion of the sale, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at approximately $294,688.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) traded up $0.19 on Friday, hitting $8.49. 625,701 shares of the stock traded hands, compared to its average volume of 328,488. Bellicum Pharmaceuticals, Inc. has a one year low of $7.41 and a one year high of $15.82. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 77.16%. The company’s revenue was up 18.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.66) EPS. equities analysts expect that Bellicum Pharmaceuticals, Inc. will post -2.93 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in shares of Bellicum Pharmaceuticals by 1.8% in the 2nd quarter. Principal Financial Group Inc. now owns 84,820 shares of the biopharmaceutical company’s stock valued at $991,000 after buying an additional 1,482 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Bellicum Pharmaceuticals by 14.9% in the 2nd quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 2,513 shares during the period. Nationwide Fund Advisors boosted its holdings in shares of Bellicum Pharmaceuticals by 30.4% in the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,620 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of Bellicum Pharmaceuticals by 5.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 73,666 shares of the biopharmaceutical company’s stock valued at $910,000 after buying an additional 4,104 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Bellicum Pharmaceuticals by 26.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 4,684 shares during the period. 55.50% of the stock is owned by institutional investors and hedge funds.

BLCM has been the subject of several research analyst reports. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Raymond James Financial reissued a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday. BidaskClub raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Jefferies Group reissued a “buy” rating and issued a $16.00 target price on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. Finally, ValuEngine raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, September 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $26.20.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/16/bellicum-pharmaceuticals-inc-blcm-cfo-alan-a-musso-sells-17117-shares-of-stock.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Insider Buying and Selling by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Stock Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related stocks with our FREE daily email newsletter.